LEUKEMIA, MYELOID, ACUTE

This study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …

This study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia live longer without their disease getting worse. About 454 adults took part…

This study tested a new drug called liposomal annamycin combined with standard chemotherapy (cytarabine) in 22 adults with acute myeloid leukemia (AML). The goal was to find the safest dose and see if the combination can control the disease. Participants had either newly diagnose…

This study tested a combination of two drugs, azacitidine and venetoclax, in 40 adults aged 45 to 65 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how safe and effective the combo is at shrinking the cancer. Participants received the drugs in 28-day cycle…

This early-phase study tested the safety of a drug called flotetuzumab in 3 adults with acute myeloid leukemia (AML) that had returned after a stem cell transplant. The drug targets a protein on leukemia cells and was given as a continuous infusion. The main goal was to find a sa…

This study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…